Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 13/20 | 0.67 |
| ▸ | PTGS1 | P23219 | 10/20 | 0.58 |
| ▸ | SDHB | P21912 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | MITF | O75030 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | STAT3 | P40763 | 1/20 | 0.53 |
| ▸ | STAT1 | P42224 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5785867 | 0.81 | PTGS2 (1.00) | PTGS2PTGS1SDHBKDM4EMITF | |
| SCHEMBL4721292 | 0.79 | SDHB (0.81) | PTGS2PTGS1SDHBKDM4EMITF | |
| SCHEMBL5787913 | 0.73 | PTGS2 (0.48) | PTGS2PTGS1 | |
| SCHEMBL28305973 | 0.73 | KDM4E (0.67) | PTGS2PTGS1SDHBKDM4EMITF | |
| SCHEMBL5790839 | 0.73 | PTGS2 (0.67) | PTGS2PTGS1SDHB | |
| SCHEMBL28307447 | 0.72 | SDHB (0.64) | PTGS2SDHBKDM4EMITFALDH1A1 | |
| SCHEMBL6408442 | 0.72 | PTGS1 (0.67) | PTGS2PTGS1KDM4EMITFLMNA | |
| SCHEMBL19805686 | 0.71 | SDHB (0.73) | PTGS2SDHBKDM4EMITFALDH1A1 | |
| SCHEMBL19805671 | 0.71 | SDHB (0.75) | PTGS2SDHBKDM4EMITFALDH1A1 | |
| SCHEMBL3560523 | 0.71 | ADORA3 (0.50) | SDHBKDM4EALDH1A1LMNASTAT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1254119-B1 | PYRIMIDINE DERIVATIVES AS SELECTIVE INHIBITORS OF COX-2 | GLAXO GROUP LTD (GB) | 2006-04-12 | — | — | EP | disclosed |
| US-6780870-B2 | TREATMENT OF THE PAIN (BOTH CHRONIC AND ACUTE), FEVER AND INFLAMMATION OF A VARIETY OF CONDITIONS AND DISEASES MEDIATED BY COX-2 | SMITHKLINE BEECHAM CORPORATION | 2004-08-24 | — | — | US | disclosed |
| US-20030109538-A1 | Pyrmidine derivatives as selective inhibitors of cox-2 | SMITHKLINE BEECHAM CORPORATION | 2003-06-12 | — | — | US | disclosed |
| EP-1254119-A1 | PYRIMIDINE DERIVATIVES AS SELECTIVE INHIBITORS OF COX-2 | GLAXO GROUP LIMITED (GB) | 2002-11-06 | — | — | EP | disclosed |
| WO-2001058881-A1 | PYRIMIDINE DERIVATIVES AS SELECTIVE INHIBITORS OF COX-2 | GLAXO GROUP LIMITED (GB) | 2001-08-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030109538-A1 | Pyrmidine derivatives as selective inhibitors of cox-2 | PTGS1, PTGS2, PTGES2 | PTGS2 2/4885PTGS1 1/4885SDHB 203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.